<DOC>
	<DOCNO>NCT02324972</DOCNO>
	<brief_summary>The primary objective study evaluate effect 12 week treatment daily administration AQX-1125 compare placebo change baseline Target Lesion Symptom Score subject mild moderate atopic dermatitis</brief_summary>
	<brief_title>Pilot Efficacy Safety Study AQX-1125 Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>1 . Male female age 18 65 year old 2 . Confirmed clinical diagnosis active atopic dermatitis ( AD ) 3 . At least 6 month history atopic dermatitis . 4 . Body Surface Area ( BSA ) cover atopic dermatitis 1 % 5 . Mild moderate atopic dermatitis ( IGA score 2 3 ) . 6 . TLSS 5 Day 0 . 7 . Subject must use nonmedicated emollient daily least ( â‰¥ ) 7 day prior Day 0 continue use emollient , frequency , throughout study . 1 . Female subject pregnant breastfeeding 2 . Unstable clinically infect atopic dermatitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Atopic dermatitis</keyword>
	<keyword>Eczema</keyword>
	<keyword>AD</keyword>
	<keyword>AQX-1125</keyword>
	<keyword>SHIP1</keyword>
</DOC>